Press Releases

KaloBios to Host Company Overview Webinar on May 10

BRISBANE, Calif., May 03, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today announced it will host a company overview webinar on Wednesday, May 10, 2017, at 1:30 p.m. ET.

Dr. Cameron Durrant, chairman and CEO, will present an update on the company, its growth initiative progress and upcoming key milestones. The webinar will feature a presentation that can be accessed via the webcast link below. A question-and-answer session will follow.

Date: Wednesday, May 10, 2017
Time: 1:30 p.m. ET (10:30 a.m. PT)

Dial-in: 1-888-267-6301
Toll/International Dial-in: 1-719-457-2734
Webcasthttp://public.viavid.com/index.php?id=124313

A telephone replay will be available approximately two hours after the call through June 10, 2017. Access the replay by dialing 1-844-512-2921 from the U.S. or 1-412-317-6671 from international locations, and entering the replay pin number: 8563194.

About KaloBios Pharmaceuticals, Inc.

KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab, for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.

CONTACT:

Investors:
Mike Cole
O: 949-259-4988
C: 949-444-1341
mike.cole@mzgroup.us

Media:
Lisa Guiterman
O: 301-217-9353
C: 202-330-3431
media@kalobios.com

Primary Logo

Source: KaloBios Pharmaceuticals Inc.